CRISPR Therapeutics' Series B - II Round

CRISPR Therapeutics raised a round of funding on June 24, 2016.

Crispr Therapeutics is a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into medicines for serious diseases, based on foundational patent estate licensed from sci…

Articles about CRISPR Therapeutics' Series B - II Round: